COMP <GO>
OVID vs PHAT // DIVIDEND YIELD & FCF PAYOUT SAFETY
Ovid Therapeutics Inc. (NASDAQ) VS. Phathom Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: OVID 2
— PHAT 3
■ METRIC PARITY
LAST: $2.56 (+4.49%) • MKT CAP: $500.0M
dividend-safety
0.00%
LAST: $6.22 (-0.95%) • MKT CAP: $503.2M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OVID VS. PHAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OVID | PHAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 87.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.50% | -35.00% | +6.50 | OVID | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.67% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -0.10% | -59.90 | PHAT | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 180.00% | 0.00 | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.46 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | PHAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.1 | 33.5 | +22.61 | OVID | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $500.0M | $503.2M | -$3.2M | PHAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OVID REV | PHAT REV | OVID GROSS % | PHAT GROSS % | OVID FCF | PHAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.3M | $175.1M | — | 87.1% | -$38.3M | -$167.0M |
| FY 2024 | $566.0K | $55.3M | — | 85.6% | -$56.0M | -$266.9M |
| FY 2023 | $392.0K | $682.0K | — | — | -$45.8M | -$137.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OVID // BETA —
PHAT // BETA —